<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476996</url>
  </required_header>
  <id_info>
    <org_study_id>ACT3986g</org_study_id>
    <secondary_id>WA20495</secondary_id>
    <nct_id>NCT00476996</nct_id>
  </id_info>
  <brief_title>A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)</brief_title>
  <acronym>SCRIPT</acronym>
  <official_title>A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-α Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in
      patients with active rheumatoid arthritis who have an inadequate response to at least one
      anti-TNF-alpha therapy. Patients will be randomized to receive placebo, 200mg of intravenous
      ocrelizumab, or 500mg of i.v. ocrelizumab on days 1 and 15. A repeat course of i.v. treatment
      will be administered at weeks 24 and 26. All patients will receive stable doses of either
      concomitant methotrexate (7.5-25mg/week) or leflunomide (10-20mg po daily) and may receive
      additional DMARDs. The anticipated time on study treatment is 1-2 years. Target sample size
      is 1000.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2007</start_date>
  <completion_date type="Anticipated">October 20, 2018</completion_date>
  <primary_completion_date type="Actual">January 21, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with ACR20 responses</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a major clinical response</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Disease Activity Score (DAS28) remission</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28 from baseline</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR response rates</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving an ACR50 response</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving an ACR70 response</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a reduction in the HAQ-DI score</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">840</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leflunomide</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Oral or parenteral repeating dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ocrelizumab</intervention_name>
    <description>Intravenous repeating dose (200mg)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ocrelizumab</intervention_name>
    <description>Intravenous repeating dose (500mg)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, ≥ 18 years of age

          -  Rheumatoid arthritis for ≥ 3 months

          -  Inadequate response to previous or current treatment with at least one anti-TNF-alpha
             agent

          -  Receiving either leflunomide or methotrexate for ≥ 12 weeks, with a stable dose for
             the last 4 weeks

        Exclusion Criteria:

          -  Rheumatic autoimmune disease or inflammatory joint disease, other than RA

          -  Any surgical procedure in past 12 weeks,or planned within 48 weeks of baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <disposition_first_submitted>August 20, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 28, 2013</disposition_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RA</keyword>
  <keyword>SCRIPT</keyword>
  <keyword>anti-CD20</keyword>
  <keyword>CD20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

